BioMarin Pharma (BMRN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance

BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.76, $0.02 better than the analyst estimate of $0.74. Revenue for the quarter came in at $766 million versus the consensus estimate of $755.94 million.

GUIDANCE:

BioMarin Pharma sees FY2026 EPS of $4.85-$5.05, versus the consensus of $4.64. BioMarin Pharma sees FY2026 revenue of $3.83-3.93 million, versus the consensus of $3.83 million.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

You May Also Be Interested In

• Kalshi in early talks for IPO - The Information
• Huntington Ingalls wins $418M Navy contract
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance